Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New research bolsters highly targeted gastro-intestinal cancer treatment

06.07.2005


Gastro-Intestinal Stroma Tumor (GIST) is a rare form of cancer of the stomach or small intestine. Up to now, only one effective treatment has existed for GIST: the use of Glivec. However, over time, this remedy becomes ineffective for a large percentage of the patients. Along with colleagues in Leuven, the research group of Peter Marynen of the Flanders Interuniversity Institute for Biotechnology (VIB), connected to the Catholic University of Leuven, has uncovered the process underlying the frequent ineffectiveness of Glivec. In addition, the researchers have shown that PKC412 - an experimental drug currently in the second phase of clinical research - can be effective in helping these patients once again. This possible alternative to Glivec, and the genetic understanding of the development of resistance to Glivec, should make it possible to prescribe a new highly targeted therapy for patients in the future.



GIST: a specific form of gastro-intestinal cancer

GIST is a rare form of gastro-intestinal cancer that strikes some 175 Belgians each year. Often, by the time it is discovered, there are already metastases in other organs, which make it impossible to remove the GIST tumors surgically. Furthermore, the other traditional cancer treatments - chemotherapy and radiation treatment - produce little result. Since 2002, there has been an effective treatment for GIST: Glivec. And up to now, this has been the only remedy for treating GIST effectively.


Why look for an alternative for Glivec?

To arrive at a definite diagnosis for GIST, a biopsy is needed to verify the presence of specific receptor proteins on the GIST cells. Cells contain certain receptors to which growth factors can bind, but GIST cells contain a defect in one of these receptors, the KIT receptor. The defective KIT receptor gives a continuous signal to the cancer cells to multiply, enabling the cancer cells to grow irrespective of the presence of the growth factors. However, the drug Glivec works by also binding to this KIT receptor and thus disabling its activity. As a consequence, the GIST cells stop growing and even die off. In contrast to chemotherapy or radiation treatment, Glivec is a highly targeted drug without many side effects. The problem is that often the tumor cells adapt themselves so that Glivec no longer has an effect on them. To find a solution for this problem is a great challenge in the treatment of GIST.

KIT adapts and resists

Peter Marynen, in collaboration with other Leuven researchers, set out to discover the mechanisms behind the origin of this tumor cell resistance to Glivec. By investigating tumor tissue from 26 GIST patients, their research revealed that, in most cases, KIT’s reactivation was a crucial factor in this process. Usually, the reactivation was the consequence of an additional alteration in KIT itself, but sometimes it was brought about by a change in another protein. This last finding is a new piece of information in cancer research.

PKC412: a new solution appears

The researchers in Leuven investigated whether an experimental drug, PKC412, could counteract the reactivation of KIT. They have demonstrated that PKC412 is indeed able to combat resistant tumors. So, once it’s on the market, this new medicine can be a good alternative for Glivec, or it can be used in combination with Glivec. At the moment, PKC412 is in Phase II clinical research on leukemia and other cancer patients. If all goes well, it is expected to come onto the market within a few years.

Research funding

This research was made possible through funding from VIB, the Catholic University of Leuven, the Belgian Federation Against Cancer, and the Flanders Research Fund for Scientific Research.

Sooike Stoops | alfa
Further information:
http://www.vib.be

More articles from Life Sciences:

nachricht What happens in the cell nucleus after fertilization
06.12.2016 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt

nachricht Researchers uncover protein-based “cancer signature”
05.12.2016 | Universität Basel

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Significantly more productivity in USP lasers

In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.

Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...

Im Focus: Shape matters when light meets atom

Mapping the interaction of a single atom with a single photon may inform design of quantum devices

Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

Simple processing technique could cut cost of organic PV and wearable electronics

06.12.2016 | Materials Sciences

3-D printed kidney phantoms aid nuclear medicine dosing calibration

06.12.2016 | Medical Engineering

Robot on demand: Mobile machining of aircraft components with high precision

06.12.2016 | Power and Electrical Engineering

VideoLinks
B2B-VideoLinks
More VideoLinks >>>